{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ATRA/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-17T00:47:44.856Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1262,"canonical_name":"Atara Biotherapeutics, Inc.","cik":"0001604464","uei":null,"lei":null,"duns":null,"ticker":"ATRA"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":27},"count":27,"timeline":[{"ts":"2026-08-26","kind":"sec.filing","form_type":"144","title":"144 — Atara Biotherapeutics, Inc. — 2026-08-26","url_slug":"/sec/cik-0001604464/144/0000905148-26-003961","accession_number":"0000905148-26-003961","importance":30},{"ts":"2026-08-26","kind":"sec.filing","form_type":"4","title":"4 — Atara Biotherapeutics, Inc. — 2026-08-26","url_slug":"/sec/cik-0001604464/4/0000905148-26-003960","accession_number":"0000905148-26-003960","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Atara Biotherapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001604464/10-q/0001193125-26-346885","accession_number":"0001193125-26-346885","importance":45},{"ts":"2026-08-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Atara Biotherapeutics, Inc. — 2026-08-12","url_slug":"/sec/cik-0001604464/8-k/0001193125-26-346857","accession_number":"0001193125-26-346857","importance":35},{"ts":"2026-07-22","kind":"sec.insider.m","reporter":"Redmile Group, LLC","title":"","shares":195211,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-22","kind":"sec.insider.m","reporter":"Green Jeremy","title":"","shares":195211,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-22","kind":"sec.insider.f","reporter":"Redmile Group, LLC","title":"","shares":60,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-22","kind":"sec.insider.f","reporter":"Green Jeremy","title":"","shares":60,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-26","kind":"sec.filing","form_type":"8-K","title":"8-K — Atara Biotherapeutics, Inc. — 2026-06-26","url_slug":"/sec/cik-0001604464/8-k/0001193125-26-285498","accession_number":"0001193125-26-285498","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Atara Biotherapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001604464/8-k/0001213900-26-068264","accession_number":"0001213900-26-068264","importance":35},{"ts":"2026-06-12","kind":"sec.filing","form_type":"S-8","title":"S-8 — Atara Biotherapeutics, Inc. — 2026-06-12","url_slug":"/sec/cik-0001604464/s-8/0001213900-26-068286","accession_number":"0001213900-26-068286","importance":30},{"ts":"2026-06-11","kind":"sec.filing","form_type":"4","title":"4 — Atara Biotherapeutics, Inc. — 2026-06-11","url_slug":"/sec/cik-0001604464/4/0000905148-26-002919","accession_number":"0000905148-26-002919","importance":30},{"ts":"2026-06-11","kind":"sec.insider.a","reporter":"Cherry Brian N","title":null,"shares":24000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"HEIDEN WILLIAM K","title":null,"shares":12000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"Fust Matthew K","title":null,"shares":12000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-09","kind":"sec.insider.a","reporter":"Ciongoli Gregory Austin","title":null,"shares":12000,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Atara Biotherapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001604464/4/0000905148-26-002570","accession_number":"0000905148-26-002570","importance":30},{"ts":"2026-05-20","kind":"sec.filing","form_type":"4","title":"4 — Atara Biotherapeutics, Inc. — 2026-05-20","url_slug":"/sec/cik-0001604464/4/0000905148-26-002571","accession_number":"0000905148-26-002571","importance":30},{"ts":"2026-05-18","kind":"sec.form144","reporter":"Nguyen AnhCo","title":"Director, Officer","shares":5981,"usd_value":62681,"security_title":"Common Stock","approx_sale_date":"2026-05-18","accession_number":"0000905148-26-002507","importance":40.012536176},{"ts":"2026-05-18","kind":"sec.form144","reporter":"Grant-Huerta Yanina","title":"Officer","shares":2754,"usd_value":28862,"security_title":"Common Stock","approx_sale_date":"2026-05-18","accession_number":"0000905148-26-002506","importance":40.005772384},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Nguyen AnhCo","title":"President and CEO","shares":5241,"price_per_share":9.1289,"usd_value":47845,"security_title":"Common Stock","importance":35.0478445649},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Grant-Huerta Yanina","title":"Chief Accounting Officer","shares":2414,"price_per_share":9.1286,"usd_value":22036,"security_title":"Common Stock","importance":35.0220364404},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Atara Biotherapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001604464/144/0000905148-26-002506","accession_number":"0000905148-26-002506","importance":30},{"ts":"2026-05-18","kind":"sec.filing","form_type":"144","title":"144 — Atara Biotherapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001604464/144/0000905148-26-002507","accession_number":"0000905148-26-002507","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Atara Biotherapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0001604464/10-q/0001193125-26-219482","accession_number":"0001193125-26-219482","importance":45},{"ts":"2026-05-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Atara Biotherapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0001604464/8-k/0001193125-26-219420","accession_number":"0001193125-26-219420","importance":35},{"ts":"2026-05-12","kind":"sec.filing","form_type":"424B5","title":"424B5 — Atara Biotherapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0001604464/424b5/0001193125-26-219518","accession_number":"0001193125-26-219518","importance":30}]}